Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and reactogenicity of repeated intradermal mRNA COVID-19 vaccines administered as a second booster dose in a Thai geriatric population.
Assantachai P, Niyomnaitham S, Toh ZQ, Thammasalee M, Pengsorn N, Monklang W, Licciardi PV, Chokephaibulkit K. Assantachai P, et al. Among authors: niyomnaitham s. Front Immunol. 2024 Jan 11;14:1302041. doi: 10.3389/fimmu.2023.1302041. eCollection 2023. Front Immunol. 2024. PMID: 38274835 Free PMC article.
Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
Wittawatmongkol O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, Boonsathorn S, Chantasrisawad N, Sudjaritruk T, Niyomnaitham S, Senawong S, Srisutthisamphan K, Quan Toh Z, Rungmaitree S, Nanthapisal S, Phanthanawiboon S, Khantee P, Techasaensiri C, Hirankarn N, Pangprasertkul S, Chokephaibulkit K. Wittawatmongkol O, et al. Among authors: niyomnaitham s. Vaccine. 2023 Sep 15;41(40):5834-5840. doi: 10.1016/j.vaccine.2023.08.021. Epub 2023 Aug 14. Vaccine. 2023. PMID: 37586956 Free article. Clinical Trial.
The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.
Angkasekwinai N, Niyomnaitham S, Sewatanon J, Phumiamorn S, Sukapirom K, Senawong S, Toh ZQ, Umrod P, Somporn T, Chumpol S, Ritthitham K, Jantraphakorn Y, Srisutthisamphan K, Chokephaibulkit K. Angkasekwinai N, et al. Among authors: niyomnaitham s. Asian Pac J Allergy Immunol. 2023 Jul 16. doi: 10.12932/AP-160123-1533. Online ahead of print. Asian Pac J Allergy Immunol. 2023. PMID: 37466962 Free article.
Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women.
Chayachinda C, Watananirun K, Phatihattakorn C, Anuwutnavin S, Niyomnaitham S, Phongsamart W, Lapphra K, Wittawatmongkol O, Rungmaitree S, Jansarikit L, Boonnak K, Wongprompitak P, Senawong S, Upadhya A, Toh ZQ, Licciardi PV, Chokephaibulkit K. Chayachinda C, et al. Among authors: niyomnaitham s. Hum Vaccin Immunother. 2023 Aug 1;19(2):2228670. doi: 10.1080/21645515.2023.2228670. Epub 2023 Jul 13. Hum Vaccin Immunother. 2023. PMID: 37439770 Free PMC article. Clinical Trial.
Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis.
Soe KK, Krikeerati T, Pheerapanyawaranun C, Niyomnaitham S, Phinyo P, Thongngarm T. Soe KK, et al. Among authors: niyomnaitham s. Front Pharmacol. 2023 May 23;14:1184552. doi: 10.3389/fphar.2023.1184552. eCollection 2023. Front Pharmacol. 2023. PMID: 37288109 Free PMC article. Review.
Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults.
Assantachai P, Niyomnaitham S, Chatthanawaree W, Intalapaporn S, Muangpaisan W, Phannarus H, Saichompoo RB, Sura-Amonrattana U, Wongprompitak P, Toh ZQ, Licciardi PV, Srisutthisamphan K, Chokephaibulkit K. Assantachai P, et al. Among authors: niyomnaitham s. J Infect Dis. 2023 Oct 3;228(7):868-877. doi: 10.1093/infdis/jiad133. J Infect Dis. 2023. PMID: 37141388 Free PMC article. Clinical Trial.
Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.
Niyomnaitham S, Jongkaewwattana A, Meesing A, Pinpathomrat N, Nanthapisal S, Hirankarn N, Siwamogsatham S, Kirdlarp S, Chaiwarith R, Lawpoolsri S, Phanthanawiboon S, Thitithanyanont A, Hansasuta P, Chaiyaroj S, Pitisuttithum P. Niyomnaitham S, et al. Int J Infect Dis. 2023 Apr;129:19-31. doi: 10.1016/j.ijid.2023.01.022. Epub 2023 Jan 20. Int J Infect Dis. 2023. PMID: 36682680 Free PMC article. Clinical Trial.
Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination.
Chatsiricharoenkul S, Niyomnaitham S, Posen HJ, Toh ZQ, Licciardi PV, Wongprompitak P, Duangchinda T, Pakchotanon P, Chantima W, Chokephaibulkit K. Chatsiricharoenkul S, et al. Among authors: niyomnaitham s. Front Immunol. 2022 Oct 4;13:1010835. doi: 10.3389/fimmu.2022.1010835. eCollection 2022. Front Immunol. 2022. PMID: 36268028 Free PMC article.
19 results